Citadel Advisors
DYN icon

Citadel Advisors’s Dyne Therapeutics DYN Stock Holding History

Citadel Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$250K Sell
13,800
-22,600
-62% -$390K ﹤0.01% 10908
2025
Q4 		$712K Buy
36,400
+5,700
+19% +$108K ﹤0.01% 8172
2025
Q3 		$388K Buy
30,700
+14,200
+86% +$162K ﹤0.01% 9740
2025
Q2 		$157K Sell
16,500
-16,900
-51% -$186K ﹤0.01% 10917
2025
Q1 		$349K Buy
33,400
+10,500
+46% +$150K ﹤0.01% 9251
2024
Q4 		$540K Buy
22,900
+2,200
+11% +$65.1K ﹤0.01% 8382
2024
Q3 		$744K Buy
20,700
+12,300
+146% +$490K ﹤0.01% 7421
2024
Q2 		$296K Sell
8,400
-11,800
-58% -$343K ﹤0.01% 9163
2024
Q1 		$573K Buy
20,200
+1,100
+6% +$24.9K ﹤0.01% 8085
2023
Q4 		$254K Buy
19,100
+13,000
+213% +$127K ﹤0.01% 9497
2023
Q3 		$54.7K Buy
6,100
+2,200
+56% +$23.7K ﹤0.01% 11655
2023
Q2 		$43.9K Sell
3,900
-10,600
-73% -$125K ﹤0.01% 11962
2023
Q1 		$167K Sell
14,500
-56,700
-80% -$736K ﹤0.01% 10466
2022
Q4 		$825K Buy
71,200
+34,300
+93% +$397K ﹤0.01% 7180
2022
Q3 		$469K Buy
+36,900
New +$423K ﹤0.01% 8597

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Citadel Advisors's DYN Position: Q1 2026 in Review

Citadel Advisors reduced its Dyne Therapeutics (DYN) stake by 83% in Q1 2026, selling an estimated $16.7M and leaving 201,144 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #4884.

Citadel Advisors first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $152M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Citadel Advisors held 201,144 shares of Dyne Therapeutics worth $3.65M as of Q1 2026.
  • Citadel Advisors sold 970,480 Dyne Therapeutics shares in Q1 2026, an estimated $16.7M.
  • Dyne Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4884 holding.
  • Citadel Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Dyne Therapeutics position peaked at $152M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.